Damora Therapeutics (DMRA) Cash & Equivalents (2019 - 2026)

Damora Therapeutics' Cash & Equivalents history runs 8 years deep, the most recent figure standing at $202.4 million for Q1 2026.

• Quarterly Cash & Equivalents rose 3280.03% year-over-year to $202.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $202.4 million (up 3280.03% YoY) and the FY2025 annual result came in at $257.6 million, up 1717.45% from the prior year.
• Cash & Equivalents was $202.4 million for Q1 2026 at Damora Therapeutics, down from $257.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $257.6 million in Q4 2025 and bottomed at $6.0 million in Q1 2025.
• A 5-year average of $51.8 million and a median of $25.1 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2025 — Cash & Equivalents tumbled 71.61% — and 2026, when it soared 3280.03%.
• Damora Therapeutics' Cash & Equivalents stood at $32.8 million in 2022, then fell by 22.85% to $25.3 million in 2023, then slumped by 43.96% to $14.2 million in 2024, then soared by 1717.45% to $257.6 million in 2025, then retreated by 21.44% to $202.4 million in 2026.
• Business Quant data shows DMRA's Cash & Equivalents at $202.4 million in Q1 2026, $257.6 million in Q4 2025, and $7.6 million in Q3 2025.